Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Cancer immunotherapy has demonstrated significant success across various malignancies.
• Checkpoint inhibitor drugs are approved for several advanced cancers, including melanoma and lung cancer.
• The US Food and Drug Administration (FDA) has expanded approvals for these therapies.

Purpose of the Study:

• To provide an update on microsatellite instability-related (MSI-related) solid tumors.
• To highlight the predictive role of MSI status in response to checkpoint immunotherapy.
• To discuss the recent FDA approval of a biomarker-based cancer treatment.

Main Methods:

• Review of current literature on MSI and cancer immunotherapy.
• Analysis of FDA approvals and clinical trial data for MSI-targeted therapies.
• Discussion of the molecular underpinnings of MSI-H tumors and their response to immunotherapy.

Main Results:

• The FDA granted accelerated approval to pembrolizumab for MSI-high (MSI-H) or mismatch repair-deficient solid tumors.
• This marks the first FDA approval of a cancer treatment based on a common biomarker (MSI-H) rather than organ site.
• MSI-H tumors exhibit specific molecular characteristics, including high tumor mutational burden and increased neoantigen expression, correlating with immunotherapy sensitivity.

Conclusions:

• Biomarker-based treatment selection, specifically MSI status, represents a paradigm shift in cancer therapy.
• MSI-H solid tumors are particularly responsive to checkpoint inhibitor immunotherapy.
• Further research into MSI-related tumors will likely enhance personalized cancer treatment strategies.